Abstract 3090
Background
Using comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) we compared the frequency of IO biomarkers in ACB, UBC and SCCB. We also report the interim results of neoadjuvant pembrolizumab in patients (pts) with muscle-invasive bladder cancer (MIBC) and variant histologies from PURE01 (NCT02736266).
Methods
Within FMI database, 143 cases of ACB, 2,142 cases of UCB and 83 cases of SCCB were subjected to CGP using a hybrid-capture based assay. Tumor mutational burden (TMB) was determined on 1.1 Mbp of sequenced DNA and microsatellite instability (MSI) was determined on 114 loci. PD-L1 expression was determined by IHC using the Ventana SP-142 assay with >1% tumor cell or immunocyte (TILs) scoring positive. Among 96 pts of PURE01, 15 had predominant variant SCCB histology.
Results
ACB patients were younger and more often female than UBC and SCCB (P < 0.0001). UBC and SCCB had a higher genomic alterations per tumor (GA/tumor) than ACB (P = 0.01). The UBC and SCCB had a significantly higher TMB than ACB (P < 0.0001) including mean TMB and TMB >/= 20 mut/Mb (P < 0.0001). CD274(PD-L1) was amplified more frequently in SCCB than ACB or UBC (P < 0.0001). MSI high status was very uncommon in all tumor types. The frequencies of PD-L1 expression in both tumor cells and TILs was higher in UBC and SCCB than in ACB (P < 0.0001). In PURE01, 5 SCCB (33.3%) achieved pT0 response, and 10 (66.7%) a pT < 2 response.Table:
930P
Adenocarcinoma (ACB) | Urothelial Carcinoma (UBC) | Squamous Cell Carcinoma (SCCB) | |
---|---|---|---|
Cases | 143 | 2,142 | 83 |
Median Age (Range) In years | 58 (24-83) | 67 (19-88) | 62 (31-88) |
Males/Females | 57/86 | 1597/545 | 45/38 |
GA/tumor | 5.4 | 7.7 | 8.2 |
MSI High | 2/106 (2%) | 11/1661 (1%) | 1/69 (1%) |
CD274 (PD-L1) gene amplification | 0 (0%) | 17 (1%) | 4 (5%) |
Mean TMB | 2.4 mut/Mb | 9.9 mut/Mb | 10.4 mut/Mb |
TMB >/= 10 mut/Mb | 14 (10%) | 697 (32%) | 26 (31%) |
TMB >/= 20 mut/Mb | 4 (3%) | 243 (11%) | 13 (16%) |
PD-L1 IHC Positive Tumor Cells | 2/11 (18%) | 76/244 (31%) | 3/10 (30%) |
PD-L1 IHC Positive TILs | 0/11 (0%) | 74/244 (29%) | 3/10 (30%) |
Conclusions
Deep sequencing reveals significant differences in IO biomarkers among the 3 major types of bladder carcinomas. UBC and SCCB have higher frequencies of high TMB and PD-L1 expression than ACB and SCCB has the highest frequency of CD274amplification. Neoadjuvant pembrolizumab showed preliminary activity in SCCB. Further study of IO biomarkers in coordination with therapy response and inclusion of SCCB appear warranted in perioperative IO trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Foundation Medicine.
Funding
Foundation Medicine.
Disclosure
J.S. Ross: Full / Part-time employment: Foundation Medicine. S.M. Ali: Full / Part-time employment: Foundation Medicine. J. Chung: Full / Part-time employment: Foundation Medicine. A.B. Schrock: Full / Part-time employment: Foundation Medicine. R. Madison: Full / Part-time employment: Foundation Medicine. B.M. Alexander: Full / Part-time employment: Foundation Medicine. A. Necchi: Advisory / Consultancy: Merck; Honoraria (self), Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (institution), Advisory / Consultancy: AstraZeneca; Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: Janssen; Honoraria (institution), Advisory / Consultancy: Clovis; Honoraria (institution), Advisory / Consultancy: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract